Claude Thebault - DBV Technologies Medical Director

Director

Ms. Claude Thebault serves as Medical Director of DBV Technologies SA. She is also Member of the Director Committee of the Company. She has over 20 years of experience in Pharmaceutical Industry
Phone33 1 55 42 78 78
Webhttps://www.dbv-technologies.com
Thebault started her career at headquarter Rhone Poulenc Rorer as an international Biostatistician Manager. She then obtained a Postdoc University diploma on Sleep Disorders including Respiratory Diseases and was involved in many clinical studies in asthma & allergy. During the first nine years inside RhonePoulenc Rorer, she held various positions, including one as international Physician Manager on Allergy products. She also worked as European Clinical Development Manager, Vaccine division, for Aventis Pasteur MSD and was a primary leadership force of R&D Department operations and projects for ALTANA Pharma Respiratory and Gastroenterology lines. She obtained a Masters degree in Biological and Medical Sciences from Universite Paris V Rene Descartes.

DBV Technologies Management Efficiency

The company has return on total asset (ROA) of (31.96) % which means that it has lost $31.96 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (67.72) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 4.63 M in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. DBV Technologies has a current ratio of 3.4, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DBV Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, DBV Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DBV Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DBV to invest in growth at high rates of return. When we think about DBV Technologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

John BientjesFlexible Solutions Internationa
66
Carolyn PittmanMinerals Technologies
57
Toru HambayashiFast Retailing Co
80
Felipe MadueoCementos Pacasmayo SAA
72
Juan VazquezCementos Pacasmayo SAA
N/A
Robert HelinaFlexible Solutions Internationa
53
Carlos RamosCementos Pacasmayo SAA
51
David FynnFlexible Solutions Internationa
61
Franklin FederMinerals Technologies
70
Robert ClarkMinerals Technologies
57
Luis BermdezBBB Foods
53
Donald WinterMinerals Technologies
72
Gianfranco ZunigaCementos Pacasmayo SAA
N/A
Carlos MateoCementos Pacasmayo SAA
N/A
Toru MurayamaFast Retailing Co
63
Pablo GrattarolaBBB Foods
51
Javier SuarezBBB Foods
47
John CarmolaMinerals Technologies
65
Barbara SmithMinerals Technologies
55
Joaquin GubbinsCementos Pacasmayo SAA
N/A
Alejandro DavilaBBB Foods
46
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. Dbv Technologies is traded on OTC Exchange in the United States. DBV Technologies SA [DBVTF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

DBV Technologies Leadership Team

Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Ehouarn, Industrial Development and Production Director
Claude Thebault, Medical Director
Wence Agbotounou, Chief Clinical Trial Officer
Laurent Martin, Director of Regulatory Affairs
Viviane Monges, Director
Didier Hoch, Director
Hugh Sampson, Chief Scientific Officer
Charles Ruban, Chief Development Officer
Nathalie Donne, Director of Bus. Devel. and Corporate Communication
Lucie Mondoulet, Director of Research Department
Chahra Louafi, Director - Representative of CDC Entreprises (Innobio)
Peter Hutt, Independent Director
Rafaele Tordjman, Director - Representative of Sofinnova Partners
Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology
Veronique Foutel, Director of Strategic Marketing
FAAAAI MD, Chief Scientific Officer, Advisor and Member of The Scientific Advisory Board
Daniel Tasse, CEO, Director
Rafale Tordjman, Director - Representative of Sofinnova Partners
Joan Schmidt, Executive Vice President General Counsel
George Horner, Director
Torbjorn Bjerke, Independent Director
Pharis Mohideen, Chief Medical Officer
PierreHenri Benhamou, Chairman of the Board, CEO
Torbjrn Bjerke, Independent Director
Mailys Ferrere, Director
Michel Rosen, Director
David Schilansky, COO

DBV Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards DBV Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, DBV Technologies' short interest history, or implied volatility extrapolated from DBV Technologies options trading.

Pair Trading with DBV Technologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Ralph Lauren could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ralph Lauren when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ralph Lauren - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ralph Lauren Corp to buy it.
The correlation of Ralph Lauren is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ralph Lauren moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ralph Lauren Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ralph Lauren can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in DBV OTC Stock

If you are still planning to invest in DBV Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DBV Technologies' history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Fundamental Analysis
View fundamental data based on most recent published financial statements
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets